The question bank is the fastest way to start, but PMHNP Helper also includes board-review planning, student resources, and plain-English guidance for psychiatric nurse practitioner students who are still learning the exam landscape.
A 56-year-old male with schizoaffective disorder and type 2 diabetes has been stable on ziprasidone 80 mg twice daily for two years. He presents for routine monitoring, and his ECG shows a QTc interval of 478 ms, increased from a baseline of 442 ms. His current medications include ziprasidone, metformin 1000 mg twice daily, and ondansetron 4 mg as needed for nausea, which he has been taking two to three times weekly for the past month due to gastroparesis. Serum electrolytes reveal potassium of 3.4 mEq/L and magnesium of 1.6 mg/dL. He is asymptomatic, denying palpitations, dizziness, or syncope. His psychiatric symptoms remain well-controlled. The PMHNP is evaluating the clinical significance of these ECG findings and potential contributing factors. Which of the following best represents the appropriate evaluation?
Explanation
QTc prolongation evaluation in patients on psychotropic medications must consider the additive effects of all QTc-prolonging agents, electrolyte status, and patient-specific risk factors. A staged approach of removing recently added offending agents and correcting electrolytes before changing psychiatric medications preserves stability while systematically reducing cardiac risk.
Key Takeaway
When evaluating QTc prolongation in a patient on a QTc-prolonging antipsychotic, the PMHNP should identify all contributing factors including concurrent QTc-prolonging medications and electrolyte abnormalities, and address correctable factors before changing the psychiatric medication.